biosimilar

Adalimumab Versus Biosimilar: How Do These Drugs Compare in RA, PsA, PsO?

Kaitlyn D’OnofrioPsoriasis | May 2, 2023

An analysis of two studies comparing adalimumab biosimilar SDZ-ADL versus reference adalimumab in patient-reported ...

Rheum Round-up: Rituximab Biosimilar Comparison, Cognitive Behavioral Therapy for OA, and more

Kaitlyn D’OnofrioRheumatology | September 11, 2020

Here are the top stories recently covered by DocWire News in the rheumatology section. In this edition, read about a ...

ABP 798, A Rituximab Biosimilar, Safe and Effective in RA Compared to Original

Kaitlyn D’OnofrioRheumatoid Arthritis | April 10, 2023

A rituximab biosimilar provided rheumatoid arthritis (RA) patients similar safety and efficacy outcomes compared to the ...

Amgen Scores Victory Over Novartis in Etanercept Biosimilar Appeal

Kaitlyn D’OnofrioRheumatology | September 11, 2023

Pharmaceutical giant Amgen won a ruling in a federal appeals court today against Novartis AG’s Sandoz, preventing the ...

Rheum Round-up: Ixekizumab’s Extended FDA Approval, RA Biosimilars Compared, and more

Kaitlyn D’OnofrioRheumatology | September 11, 2023

Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about the ...

Mabura versus Humira in Active Rheumatoid Arthritis Patients: An Adalimumab Biosimilar Comparison

Kaitlyn D’OnofrioRheumatoid Arthritis | September 11, 2023

Researchers recently compared the safety, efficacy, and pharmacodynamics of adalimumab manufactured by Hetero and ...

With Introduction of Biosimilars, Biologics Prices Have Decreased

Kerri FitzgeraldOncology | April 24, 2023

The net prices of biologic agents have decreased following the introduction of biosimilar or other alternatives, ...

Rheum Round-up: Different Effects of Rheumatic Diseases, Humira Biosimilar Approval, and more

Kaitlyn D’OnofrioRheumatology | November 22, 2019

Here are the top stories covered by DocWire News this week in the Rheumatology section. In this edition, read about how ...

Kaitlyn D’OnofrioRheumatoid Arthritis | April 10, 2023

The Food and Drug Administration (FDA) granted approval to Pfizer’s Abrilada (adalimumab-afzb), a biosimilar to Humira ...

A Comparison of Biosimilar versus Originator Rituximab in RA and Non-Hodgkin’s Lymphoma

Kaitlyn D’OnofrioRheumatoid Arthritis | May 2, 2023

A new systematic review compared biosimilar rituximab to the originator drug in patients with rheumatoid arthritis (RA) ...

Amgen Receives Victory in Arthritis Drug Enbrel Case

Kaitlyn D’OnofrioRheumatology | August 16, 2019

A U.S. judge ruled in favor of Amgen on the validity of two patents pertaining to the company’s drug Enbrel ...

Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review

DocWire News EditorsOncology | September 11, 2023

Healthcare resource utilization (HRU) increases in patients with non-medical switching (NMS) from biologic originators ...

Biosimilars: A Value Proposition

DocWire News EditorsOncology | September 11, 2023

The emergence of biosimilars in the marketplace promotes economic stability and enhances patient access to biological ...

Rheum in Review: Comorbidities in Pediatric Psoriasis, Biosimilar Safety, and Electroacupuncture

Kaitlyn D’OnofrioRheumatology | May 31, 2019

Here are the top stories covered by DocWire News this week in the Rheumatology section. In this edition, read about the ...

Etanercept Biosimilar Safe and Effectively Treats RA

Kaitlyn D’OnofrioRheumatoid Arthritis | April 7, 2023

The results of a recent trial found that patients with moderate-to-severe rheumatoid arthritis (RA) who switched from ...

DocWire News EditorsRheumatology | April 10, 2023

As biologics, biosimilars, and biomimics continue to emerge in Latin American countries, there remain regulatory ...

Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: Overview of the Literature and Perspective

DocWire News EditorsGastroenterology | April 10, 2023

Switching from the originator infliximab (IFX-O) to its biosimilar (IXF-B) is acceptable in patients with inflammatory ...

Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals

DocWire News EditorsOncology | April 10, 2023

Managed care and specialty pharmacy professionals have mostly favorable views regarding the safety and efficacy of ...

Switching to Biosimilars: Current Perspectives in Immune-Mediated Inflammatory Diseases

DocWire News EditorsRheumatology | April 10, 2023

There exists a myriad of benefits which support switching patients with immune-mediated inflammatory disease (IMIDs) ...

Second Etanercept Biosimilar, ETICOVO, Wins FDA Approval

Kaitlyn D’OnofrioRheumatology | September 11, 2023

The Food and Drug Administration (FDA) approved a second biosimilar for etanercept (ENBREL, Amgen). ...